Ohio Board Of Pharmacy Awards Dispensary Certificate Of Operation In Youngstown

State_of_Ohio_Board_of_pharmacy_logo2COHIO:

The State of Ohio Board of Pharmacy today awarded a Dispensary Certificate of Operation to Leaf Relief, located at 4323 Market St., Youngstown.

The interactive map of Dispensaries with Certificates of Operation will be updated within the next 48 hours.

Ohio Medical Marijuana Sales Figures – March10, 2019

Update from the Ohio Medical Marijuana Control Program

Update from the Ohio Medical Marijuana Control Program

The following are program sales totals from 1/16/2019 to 3/10/2019:

  • Total Sales: $1,854,900
  • Total Volume of Product Sold: 245 pounds

The Ohio Medical Marijuana Control Program will provide weekly sales figures through April 1st, after which a monthly report will be made available.

Patient registration information will continue to be reported on a monthly basis.

Tilray Announces Successful Medical Cannabis Harvest In Portugal; Provides Update On European Operations

CANADA: Tilray, a global leader in cannabis research, cultivation, production and distribution, announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. has completed a successful harvest of medical cannabis at the Company’s European Union (EU) Campus in Portugal.

Tilray_LogoTilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals nearly 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs 100 people, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months.

“Our harvest in Portugal is an exciting milestone for the company as we continue to build our multinational supply chain of high-quality medical cannabis,” said Sascha Mielcarek, Managing Director, Europe. “We look forward to utilizing the capacity of Tilray Portugal to supply the medical cannabis market in Europe as we expand our operations.”

Tilray was the first licensed medical cannabis producer to successfully import medical cannabis products into the EU and the first licensed medical cannabis producer in North America to obtain Good Manufacturing Practice (GMP) certification in accordance with the European Medicines Agency’s (EMA) standards. Tilray has established sales and distribution arrangements to distribute medical cannabis through major pharmaceutical distribution channels throughout Germany and the European Union. The Company has also formed a global alliance with Sandoz AG, a worldwide leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to increase availability of high quality medical cannabis products around the world in jurisdictions where regulations permit.

In addition to its EU Campus in Portugal, Tilray currently operates multiple state-of-the-art production and processing facilities in Canada. Tilray looks forward to hosting an official ribbon-cutting event at its EU Campus in Portugal later this spring.

CannaTech Tel Aviv 2019 Returns April 1-3, 2019

ISRAEL: Israel’s CannaTech conference returns to Tel Aviv, the global capital of medical cannabis —  a place where innovative Israeli researchers and scientists, high tech experts and “Start-Up Nation” entrepreneurs have fused their knowledge and skills with other world leaders in the industry to develop cutting edge expertise.

iCANN logo final

The main events will take place at Trask, in the Tel Aviv Port on the Mediterranean Sea, from April 1-3, 2019.

The cannabis economy is the world’s fastest growing industry, with an outstanding track record of research and development and a significant contribution to a vast array of medical treatments. Economists foresee the potential overall market worth of cannabis related goods and products in the tens of billions of dollars in the next decade.

Companies, entrepreneurs, researchers, investors and other stakeholders will meet at the CannaTech Innovation Summit to connect and learn about the latest opportunities in the booming medical cannabis market as well as the newest cutting-edge technologies and research in the field.

Saul Kaye, CEO and founder of CannaTech and iCAN-Israel Cannabis said, “Now that Israel has legalized export of medical cannabis, local industry and Israel’s research institutions, already decades ahead of any cannabis R&D facilities in the world, will flourish and continue to create global partnerships with countries that are witnessing unprecedented demand.  Israel will be helping patients across continents obtain the world’s safest and most effective cannabis-based medicine and products, and I could not be prouder that Israel and CannaTech are leaders in this ecosystem.”

At CannaTech attendees will hear from and meet the industry’s most serious thought leaders and market disrupters from around the world.  Topics will include Ag-Tech, Regulation, Medical Research, Investment, Media/New Cannabis Communication, Innovation, Hemp and Sustainability.

To learn more about the CannaTech Tel Aviv Innovation Summit, purchase tickets and subscribe to event updates and speakers lists click here.  To learn about iCAN, the Summit’s organizers,  click here for the iCAN website.

Ohio Board of Pharmacy Awards Dispensary Certificates Of Operation In Elryia & Jackson

OHIO: The State of Ohio Board of Pharmacy has awarded a Dispensary Certificate of Operation to Clubhouse Dispensary, located at 709 Sugar Ln., Elyria. and to Buckeye Botanicals LLC, located at 3 Acy Ave., Jackson.

List of all Dispensary Certificates of Operation

Ohio dispensary 2 19

 

Maryland Medical Cannabis Forum Is Thursday, November 8, 2018

Presents an In-Depth Discussion of MMJ Research and Practice

MARYLAND – Maryland doctors can enhance their knowledge about medical cannabis treatment at the inaugural Maryland Medical Cannabis Forum (MMCF), on Thursday, November 8th in Baltimore.  The MMCF was created to provide to the Maryland medical community current and credible information on the state of medical cannabis research and practices–and how it affects the 35,000-and-growing Maryland MMJ patients. Discussion topics for the evening include:

  • The endocannabinoid system and its relation to treating diseases
  • Cancer case studies utilizing cannabis for symptom relief and pain management
  • Cannabis treatment for neurological disorders such as Alzheimer’s, epilepsy and autism
  • Cannabis and reduction in opioid dependency and other prescription medications
  • Proper dosing and understanding common side effects

The evening kicks off at 5:00 p.m. with a cocktail and hors d’oeuvres reception. The program begins at 6:30 p.m. with featured speakers Dr. Jokūbas Žiburkus (Canntelligence) and Dr. Dustin Sulak (Healer.com), followed by a panel discussion hosted by CNBC’s Tim Seymour and including Sid Taubenfeld of Tikun Olam’s TO Pharma and Joy Strand, Executive Director of the Maryland Medical Cannabis Commission, among others.

The MMCF is proud to have the support of MedChi (the Maryland State Medical Society), and sponsors including global medical cannabis brand Tikun Olam, MariMed Advisors and Kind Therapeutics to establish this event as a comprehensive and trustworthy forum for up-to-date information on medical cannabis for Maryland doctors to provide their patients. The registration fee for MMCF is $75, $50 for MedChi members; visit www.medicalcannabisforum.org.

FSD Pharma Announces Launch of IBS Clinical Study

CANADA: FSD Pharma has announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics. The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.

The double-blind, randomized, placebo-controlled study will enroll 20 patients in a cross-over design to comply with the highest standards of rigorous scientific validity and certification demands of international medical regulatory authorities.

Under the terms of FSD’s strategic agreement with SciCann, the Company holds exclusive manufacturing and distribution rights for the “Steady Stomach” product in Canada.

The study’s principal investigator is Dr. Bryan Doner of Compassionate Care Certifications Centers in Pittsburgh, Pennsylvania and the CRO is Affinity Bio Partners, led by CEO Dr. Christina DiArcangelo Puller.

Dr. Raza Bokhari, CEO of FSD Pharma, stated, “This innovative clinical study aims to demonstrate the safety and efficacy of this easy-to-administer, side-effect-free therapy for a very common disease. Although rarely spoken about, IBS causes suffering to many patients around the world by dramatically reducing quality of life. The launch of this study marks another important milestone for FSD on its way to becoming a leading supplier of superior and differentiated medical, cannabis-based therapies for patients. Together with our partner SciCann, FSD is working tirelessly towards the development of novel and disruptive cannabinoid-based therapies for the world’s most under-treated diseases and irritable bowel syndrome is high on our list of target indications.”

Dr. Zohar Koren, co-founder and CEO of SciCann Therapeutics, stated, “The prevalence of irritable bowel syndrome is estimated at 10-15 percent of the global population. This is an under-diagnosed, hard-to-treat condition that causes an estimated cost to society of over US$21 billion annually in direct medical expenses and indirect costs associated with loss of productivity1. Based on our research, we believe that our proprietary “Steady Stomach” CBD combination product can serve as a new treatment standard to improve the lives of patients. We are looking forward to reporting on the results of this clinical study. ”

Tilray Gets DEA OK To Import Medical Cannabis Study Drug For Clinical Trial At University Of California San Diego Center For Medicinal Cannabis Research

CANADA: Tilray has announced that the U.S. Drug Enforcement Administration (DEA) has granted approval to import a cannabinoid study drug into the United States from Canada for a clinical trial at the University of California San Diego (UC San Diego) Center for Medicinal Cannabis Research (CMCR) examining its safety, tolerability and efficacy for Essential Tremor (ET).

Agreement represents major milestone recognizing medical cannabis as a conventional medicine for patients in need

Tilray is providing a cannabinoid formulation for the trial in capsule form, which will allow researchers to test an investigational drug product containing two active ingredients extracted from the cannabis plant, cannabidiol (CBD) and tetrahydrocannabinol (THC). Dr. Fatta Nahab, a board-certified neurologist and director of the Functional Imaging of Neurodegenerative Disorders Lab at the UC San Diego Health’s Movement Disorder Center, will serve as the principal investigator for the study. It is expected to begin in early 2019 with financial support from Tilray and the International Essential Tremor Foundation.

“Tilray is proud to support this crucial research,” says Dr. Catherine Jacobson, Director of Clinical Research at Tilray. “If this study can identify cannabinoids as a potential treatment for patients suffering from essential tremor, we can conduct further research and potentially provide alternative effective methods of relief for the high numbers of patients with ET.”

Essential Tremor is a neurological movement disorder characterized by involuntary and rhythmic shaking. ET has extremely high prevalence rates; 0.4% of the general population suffer from ET, and that figure rises to 4.6% to 6.3% among those 65 and older. Essential Tremor can have a significant impact on a patient’s quality of life, causing embarrassment, social withdrawal, disability, and loss of occupation. Many patients do not experience relief with the current drugs on the market or find the side-effects of these drugs to be unbearable.

Vertical Companies And Galenas Form Strategic Partnership For The Ohio Legal Medical Cannabis Market

CALIFORNIA: Vertical Companies and Galenas are pleased to announce a strategic partnership between the two businesses. Vertical is among the first and largest vertically integrated companies in the legal cannabis industry. Galenas is a newly-licensed Ohio cultivator and is currently constructing its state-of-the-art medical marijuana cultivation facility in Akron, Ohio.

“We are extremely happy to be aligning with Vertical. They’ve built one of the best teams in the American cannabis industry, and having access to their management group and resources is only going to allow us to provide better care and higher quality medicine to medical patients,” said Geoffrey Korff, president of Galenas. “We’ve designed this new facility to also demonstrate that quality, sustainability, energy efficiency, and profitability are not all mutually exclusive in this space.”

Once completed, Galenas’ facility will be one of the most environmentally friendly and sustainable indoor medical marijuana cultivation facilities in North America dedicated to producing the highest quality, organically grown marijuana that will be available in the Ohio market.

“This strategic alliance with Galenas continues Vertical’s strategy of building out a national footprint in all legal cannabis markets for our brands,” said J. Smoke Wallin, President of Vertical, who leads distribution, sales and marketing. He continued: “For us it’s always about the people and Geoff demonstrates the leadership qualities we look for in every partner. With 11.7 million people, Ohio is the seventh largest U.S. state and represents a tremendous growth opportunity for the cannabis industry. We couldn’t be more excited to bring our team’s expertise to assist Geoff as he builds Galenas into the market leader.”

 

Tilray Exports Medical Cannabis Genetics To The European Union

PORTUGAL: Tilray, a GMP-certified global leader in medical cannabis research and production, today announced that the company has successfully exported live medical cannabis genetics from its flagship British Columbia, Canada facility to its European Union Campus in Cantanhede, Portugal. The announcement is the first time a company has legally exported live cannabis genetics from North America to Europe and marks another strategic milestone as Tilray develops its EU Campus into the region’s leading medical cannabis research and production facility.

“Tilray is proud to bring our medical cannabis research and production expertise to the European Union to better serve patients, health care providers, and researchers throughout the continent,” said Brendan Kennedy, Tilray CEO. “Bringing live plants to Portugal is another important milestone for our company and our industry.”

In September, Tilray announced plans to invest up to €20 million in a European Union Campus (EU Campus) after receiving licenses to import genetics and cultivate medical cannabis from the Government of Portugal. To establish the EU Campus, Tilray is investing in multiple facilities located in and around the BIOCANT Research Park in Cantanhede. The EU Campus will include indoor and greenhouse cultivation sites, as well as facilities to process, package, and distribute medical cannabis and cannabinoid-derived medical products. As a part of the BIOCANT biotechnology and life sciences research park, the EU Campus will serve as a hub supporting Tilray’s clinical research and product development efforts across Europe.

Phase one of the project, which is expected to be complete in the first half of 2018, includes an indoor laboratory and genetics bank (completed), a 10,000 m2 greenhouse (under construction), and a 3,000 m2 processing facility (under construction). Subsequent phases, which are expected to be completed by 2020, will add 15,000 m2 of greenhouse cultivation space and another 3,000 m2 for processing. Over the next three years, the project is expected to create 100 direct jobs, including highly skilled positions.

Tilray is investing aggressively to expand its operations in the European Union in response to considerable unmet need for high-quality medical cannabis. In October, Tilray achieved two other strategic milestones in the EU by becoming the first medical cannabis licensed producer to import full-spectrum medical cannabis extract products into Germany for nationwide distribution through pharmacies and the first licensed medical cannabis producer to sign an agreement with an established pharmaceutical wholesaler (NOWEDA). As the first full-spectrum extracts available in Germany, Tilray’s products are an important addition to Germany’s pharmaceutical market for medical cannabis products. Tilray products are also currently available in the EU member states of Croatia and Cyprus. In the coming months, the company plans to announce additional EU exports and research partnerships.